Clinical trials: Alzheimer Disease 2
Alzheimer Disease
Optimizing Care for Patients With Dementia
Of the 1.4 million nursing home (NH) residents in long term care facilities, more than half have Alzheimer's disease or dementia.
- Trial name
- NCT03442322
- Testing
- transdisciplinary approach, multidisciplinary approach
- Where
- United States
- Volunteers
- 53 people
- Sponsor
- University of Pittsburgh
Diabetes, Alzheimer Disease
The Diabetes Prevention Program Outcomes Study AD/ADRD Project
The DPPOS AD/ADRD project will address the overarching question: What are the determinants and the nature of cognitive impairment among persons with pre-diabetes (PreD) and type 2 diabetes (T2D), who are a high-risk group for…
- Conditions
- Diabetes, Alzheimer Disease, Dementia, Vascular, Dementia
- Trial name
- DPPOS-4 (NCT05704309)
- Where
- 27 sites in United States
- Volunteers
- 1,976 people, healthy volunteers welcome
- Sponsor
- Marinella Temprosa
Late Onset Alzheimer Disease
Response to Donepezil, Drug Plasma Concentration and the CYP2D6 and APOE Genetic Polymorphisms
Pharmacological treatment of AD is currently based on cholinesterase inhibitors (ChEI) and memantine, which have been shown to lead to modest, although effective, clinical benefits.
- Trial name
- NCT03349320
- Volunteers
- 37 people, healthy volunteers welcome
- Sponsor
- Federal University of Minas Gerais
Late Onset Alzheimer Disease
Expanded Access With Trappsol(R) Cyclo (TM) for an Individual Patient With Late Onset Alzheimer's Disease
To afford urgent access to a potential-disease modifying treatment, Dr. Diana Kerwin, in partnership with CTD Holdings, the manufacturer of Trappsol (R) Cyclo(TM), will administer the product to a patient with Alzheimer's Disease…
- Trial name
- NCT03624842
- Testing
- Trappsol (R) Cyclo (TM)
- Sponsor
- Cyclo Therapeutics, Inc.
COVID-19
A Study to Evaluate the Safety and Immunogenicity of Ad5-nCoV and Ad5-nCoV-IH in CoronaVac Immunized Children and Adolescents
This is a multicenter, randomized, and open-label study to evaluate the immune responses and safety profiles of children aged 6-12 years and adolescents aged 13-17 years receiving Ad5-nCoV (intramuscular injection) or Ad5-nCoV-IH…
- Trial name
- NCT05169008
- Testing
- Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector), Recombinant COVID-19 vaccine (adenovirus type 5 vector) for Inhalation (Ad5-nCoV-IH)
- Where
- 2 sites in Chile
- Volunteers
- 91 people, healthy volunteers welcome
- Sponsor
- CanSino Biologics Inc.
ALS, Amyotrophic Lateral Sclerosis
NYSCF Scientific Discovery Biobank
The New York Stem Cell Foundation (NYSCF) Research Institute is performing this research to accelerate diverse disease research using cells from the body (such as skin or blood cells) to make stem cells and other types of cells…
- Conditions
- ALS, Amyotrophic Lateral Sclerosis, Alzheimer Disease, Alzheimer Disease, Early Onset
- Trial name
- NCT06203106
- Testing
- Biological Sample Collection
- Where
- United States
- Volunteers
- 10,000 people
- Sponsor
- New York Stem Cell Foundation Research Institute
Apathy, Alzheimer's Disease
Apathy in Dementia Methylphenidate Trial 2
Apathy in Dementia Methylphenidate Trial 2 (ADMET 2) is a Phase III, placebo-controlled, masked, 6 month, multi-center randomized clinical trial sponsored by National Institutes of Aging involving 200 participants with…
- Trial name
- ADMET2 (NCT02346201)
- Testing
- Methylphenidate
- Where
- 10 sites in United States, Canada
- Volunteers
- 200 people
- Sponsor
- Johns Hopkins Bloomberg School of Public Health
Depression, Suicidal Ideation
BRITEPath- Phase 2
BRITEPath (BP) aims to support co-located mental health clinicians in the development of a high quality, effective, and personalized safety plan for referred patients who screen positive for depression and/or suicidal ideation.
- Trial name
- NCT04672798
- Testing
- BRITEPath, Treatment As Usual (TAU)
- Where
- 6 sites in United States
- Volunteers
- 101 people
- Sponsor
- University of Pittsburgh
Agitation Associated With Alzheimer's Disease, Alzheimer's Type
Safety Follow-up Study for Subjects With Agitation Associated With Dementia of the Alzheimer's Type Who Previously Participated in a Double-blind Trial of Brexpiprazole or Placebo
To follow-up on the safety of subjects who were previously treated in a double-blind trial of brexpiprazole.
- Conditions
- Agitation Associated With Alzheimer's Disease, Alzheimer's Type, Mental Disorder, Nervous System Diseases
- Trial name
- NCT02192554
- Where
- 84 sites in United States, Bulgaria and 10 more
- Volunteers
- 450 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Alzheimer's Disease
Phase 2 Study to Examine Grape Seed Extract as an Anti-Oligomerization Agent in Alzheimer's Disease (AD)
Alzheimer Disease (AD) is a progressive brain disease generally known as senile dementia. Our proposed study will establish safety and pharmacokinetics of Meganatural-AZ GSPE in AD subjects.
- Trial name
- NCT02033941
- Testing
- Meganatural-Az Grapeseed Extract
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Hillel Grossman
Atopic Dermatitis
TRuE AD2 - An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis
The purpose of this study is to assess the efficacy of ruxolitinib cream in adolescents and adults with atopic dermatitis (AD).
- Trial name
- NCT03745651
- Testing
- Ruxolitinib cream, Vehicle cream
- Where
- 66 sites in United States, Bulgaria and 5 more
- Volunteers
- 618 people
- Sponsor
- Incyte Corporation